about
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaIdentification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytesInvolvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cellsAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceRAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytesA novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemiaThe JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.Ponatinib in refractory Philadelphia chromosome-positive leukemias.Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cellsEngagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cellsRegulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cellsThe non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation.Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activityGrowth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugateSurvey of activated FLT3 signaling in leukemiaCrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitorsFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsBCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1.Activation of a CrkL-stat5 signaling complex by type I interferons.Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.T cell activation-dependent association between the p85 subunit of the phosphatidylinositol 3-kinase and Grb2/phospholipase C-gamma 1-binding phosphotyrosyl protein pp36/38.Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiThe NIH BD2K center for big data in translational genomics.Chronic myelogenous leukemia.Generation of a large library of point mutations in polyoma middle T antigen.RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in miceA gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
P50
Q24299821-2D8C8819-4DA0-4794-AF20-6BEC343C858FQ24313371-53912E4A-9E48-4515-BC57-799BB31075F2Q24317734-3CDF7A60-8D06-42C5-89E8-DEF621755FDEQ24648017-A578DFC5-4E47-4DAA-92A7-7A91D97C7C78Q24669953-554DAE2C-FCDF-4610-9EE5-D2A5E4116A8EQ24685013-8872180E-76F9-418D-9B0C-CB53FD496EACQ27266125-7E216C08-FDFA-40FA-8093-2B471B5C7696Q27824804-0A88739F-4955-4C5C-98AD-377EFFDD314FQ27851967-E4515164-294D-49DD-82D7-4B2772807A0BQ27852275-866A2A81-7254-4727-AF91-5B07166D05A3Q27853214-940C9D03-57A3-4EB9-AC22-08EF20A29A73Q28141558-EF837D59-49D4-417F-9906-81B848D24576Q28199681-AC6F822D-F2D2-4100-9FD2-BC7D6A764A11Q28241124-0B051D83-18F5-4D4A-A2B9-E5F86B8354FAQ28291812-6E793445-9911-4E86-9A85-1F07742AB412Q28306400-F4FA86F4-A6CD-4B1C-AF35-EC7E07CEC89CQ28366332-B7A817A0-9B87-45CB-9DE4-45FBB5F4D363Q28472865-1485FC7E-1768-47CA-B1DC-EF4F759880F1Q28473957-2450EAF5-8ECB-47E0-A330-D9FCC7180140Q28477934-7F6516D8-6C12-4E74-A24B-C73253FF1905Q28609404-421FF7F7-1420-48BA-BCE1-4B4F9A69CF09Q29614280-D84EE0FC-73D6-4968-AEAC-A03A7FB2750BQ29618610-73B2124B-A63B-401D-B459-B32C347867CAQ30156840-41A31B80-63EA-421B-A57B-8D7CDEA53900Q30167565-8BDA5B2A-BD7F-4221-92EF-AA0EBBED90F9Q30175923-54B371D0-B91B-4060-931B-2FACE95B8C08Q30175971-DE21ED6F-40B8-4D49-97DE-8C222083E534Q30176501-62DB78BD-9C97-47D5-BBEC-AECDE2B7D20FQ30193176-48B41B84-2C61-4A8D-8D8E-D48CAAC1590FQ30357011-3317F15C-E3D2-4023-A8A6-F2B95434B1D8Q30980407-F548B6D4-5904-401B-9206-1E92D244970BQ31811587-469FD3F7-3136-470A-879F-992F4008AEEBQ33240306-53D4BDAE-850D-4AB8-ABCD-5A9650F3FD95Q33306326-3A9D44E1-1776-4A9E-8B8A-598ED0F8AF1CQ33343973-EB7B05DE-B14A-471E-8A2B-297F7230C3A7Q33376263-1B53BADA-5850-403E-85FC-3D7D81B3C541Q33402939-CB298063-B6F1-4495-9045-56BA7D214477Q33417454-286F63BB-2174-43BA-A575-D6A98B461897Q33510153-63EF87DA-FCAB-4C87-980C-6F8217F6DB37Q33597519-DFD3EA34-C293-46B4-87ED-95A0483DF667
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brian J. Druker
@ast
Brian J. Druker
@en
Brian J. Druker
@es
Brian J. Druker
@sl
type
label
Brian J. Druker
@ast
Brian J. Druker
@en
Brian J. Druker
@es
Brian J. Druker
@sl
prefLabel
Brian J. Druker
@ast
Brian J. Druker
@en
Brian J. Druker
@es
Brian J. Druker
@sl
P108
P106
P108
P1153
7103025565
P21
P31
P496
0000-0001-8331-8206